Drug Profile
Pilaralisib - Exelixis/Sanofi
Alternative Names: SAR-245408; XL-147Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Exelixis; Sanofi
- Class Antineoplastics; Quinoxalines; Small molecules; Sulfonamides
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Endometrial cancer; Glioblastoma; Lymphoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 20 Jan 2021 Discontinued - Phase-I for Glioblastoma (Monotherapy, Recurrent) in USA (PO) (Exelixis pipeline, January 2021)
- 20 Jan 2021 Discontinued - Phase-I for Lymphoma (Late-stage disease, Second-line therapy or greater) in Belgium (PO) (Exelixis pipeline, January 2021)
- 20 Jan 2021 Discontinued - Phase-I for Lymphoma (Monotherapy) in Spain, USA (PO) (Exelixis pipeline, January 2021)